July 11, 2014 10:28 PM ET

Biotechnology

Company Overview of Tranzyme, Inc.

Executive Profile

Daniel F. Veber Ph.D.

Former Member of Advisory Board, Tranzyme, Inc.
AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 3 different industries.

See Board Relationships
----

Background

Dr. Daniel F. Veber, Dan, Ph.D, serves as Medicinal Chemistry Advisor of Tranzyme Inc. Dr. Veber serves as an Independent Consultant to the Pharmaceutical Industry. He serves as Scientific Advisor of The Institute for OneWorld Health, Euroscreen S.A. He serves as Member of Scientific Advisory Board of Aileron Therapeutics Inc. From 1993 to 2002, he served as Director of Medicinal Chemistry for SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline). He was responsible ...

Corporate Headquarters

5001 South Miami Boulevard
Durham, North Carolina 27703

United States

Phone: 919-474-0020
Fax: 919-474-0025

Board Members Memberships

2004-N/A
Former Member of Advisory Board

Education

MS 1962
Yale University
PhD 1964
Yale University
Bachelor's Degree
Yale University
BA 1961
Yale University

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tranzyme, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.